Jefferies initiates FMC stock coverage with hold on pricing headwinds

Jefferies initiated FMC at Hold with a $6.00 price target, below the stock’s cited $6.20 price; shares were up 34% over the past week but down 54% year to date. FMC reported Q3 2026 adjusted EPS of -$4.41 and revenue of $105.6 million, and cut full-year free cash flow guidance to -$350 million to -$150 million. Jefferies expects pricing and demand headwinds to persist through 2027 but projects EBITDA recovering to $650 million-$730 million in 2027 and $760 million-$840 million in 2028, versus negative $275 million over the last twelve months.

Analysis

The setup is a credibility-and-liquidity test, not a conventional cheap-stock rerating. The projected 2027 EBITDA recovery requires the commercial reset to restore replenishment and pricing before customer destocking and patent-related pressure overwhelm the benefit of restructuring and new products. The negative free-cash-flow outlook makes that timing consequential: if operating performance lags, cash consumption can impair strategic flexibility and keep equity value exposed to financing or further restructuring risk. Conversely, channel normalization could produce a sharp rebound because expectations appear depressed—but the forecast is a management/analyst scenario, not evidence that the inflection has begun.

The recent rally leaves little cushion against another guidance reset, while the cited $6 target is close to the article’s stated share price; this is not, by itself, proof of fair value. A key data-quality check is required before sizing: the reported quarterly revenue and underlying sales figures differ materially, as do the stated EBITDA scopes. Reconcile commercial charges, underlying business, and consolidated cash flow rather than extrapolating either figure. Near term (days to weeks), momentum can dominate. Over 1–3 months, order replenishment, cash burn, and updated guidance are the relevant catalysts. Over 6–18 months, successful product launches and pricing stabilization determine whether the 2027 recovery is deliverable. Crop-protection peers could benefit if FMC cedes customer relationships or shelf space, but a broad sector read-through is unwarranted without evidence of share gains.

Key Decisions for Investors

• Do not chase the one-week rally. For a tactical bearish expression, consider a defined-risk FMC put spread only after a failed retest or a close back below the post-rally breakout area; avoid an outright short while momentum and turnaround optionality remain high.
• Keep a recovery position on watch, not in the base case, until the next report shows improving replenishment, a credible reduction in cash outflow versus the negative $150 million to negative $350 million full-year FCF range, and progress toward the 2027 EBITDA bridge.
• Verify the revenue and EBITDA scope differences, commercial-charge treatment, liquidity, and any financing requirements before sizing. If reported operating cash flow or guidance deteriorates again, that falsifies the recovery path and strengthens the downside case.
• A sustained recovery in channel orders and pricing, alongside lower cash burn without further material guidance cuts, would invalidate the fade thesis; reassess rather than adding to a short.